Document Type

Article

Publication Title

Cureus

Abstract

Background

Clinical trials play a vital role in advancing evidence-based orthopedic care, yet trial discontinuation and nonpublication limit transparency and reduce the availability of clinically valuable data. In total hip arthroplasty (THA), incomplete dissemination of trial outcomes may have important ethical and clinical implications.

Methods

A registry-based cross-sectional analysis of randomized Phase III and IV THA clinical trials registered on ClinicalTrials.gov between 2000 and 2024 was performed. Trials registered at least two years before the search date (January 2026) were included. Trial characteristics, including funding source, intervention type, enrollment size, blinding, number of centers, and recruitment location, were extracted. Publication status was determined through registry-linked publications and independent database searches. Associations were analyzed using chi-square or Fisher’s exact tests (p < 0.05).

Results

Of 168 identified trials, seven unrelated to THA were excluded, leaving 161 trials for analysis. Fifty trials (31.1%) were discontinued, and 111 (68.9%) were completed. Among completed trials, 26 (23.4%) remained unpublished. Discontinuation was significantly associated with intervention type (p = 0.0015) and blinding (p = 0.022), with higher rates in device trials (59.3%) and unblinded studies (55.9%). Nonpublication was significantly associated with industry funding (39.3% vs. 18.1%, p = 0.022) and intervention type (p = 0.044).

Conclusions

A substantial proportion of THA clinical trials are discontinued or remain unpublished, contributing to data loss and potential bias in the orthopedic literature. Improved reporting compliance is needed to support transparency and evidence-based orthopedic practice.

DOI

10.7759/cureus.117850

Publication Date

10-13-2026

Keywords

adult reconstruction, hip replacement, orthopedic surgery, research transparency, total hip arthroplasty

ISSN

2168-8184

Share

COinS